Collegium Pharmaceutical (COLL) as of March 31, 2026 presents a deeply negative liquidation recovery posture that is structural to its business model, not a distress signal per se. Under the liquidation lens, the asset side is dominated by intangibles and goodwill, which receive zero recovery: finite-lived intangible assets net of accumulated amortization stand at $614.0M (gross $1.59B, accumulated amortization $972.1M), and goodwill is $145.9M. Both are zeroed in liquidation. Tangible asset recovery is limited: cash and equivalents of $268.6M recover at 100%; restricted cash of $20.9M current and $1.1M noncurrent recover at 100%; marketable securities (available-for-sale) of $157.3M recover near par given liquid AFS portfolio; AR of $228.8M recovers at 90-95% (call it ~$210M); inventory of $42.7M current plus $9.7M noncurrent recovers at ~60% (~$31M); PP&E net of $11.7M recovers at 50-70% (~$7M); deferred tax asset of $113.6M has uncertain liquidation value, likely zero in a wind-down; prepaid/other current of $32.6M and other noncurrent of $16.1M recover at a steep haircut. Aggregate haircutted tangible asset recovery is roughly $820-850M before zeroing intangibles/goodwill. Against this, the liability stack at face value is material: 2025 Term Loan outstanding principal $572.8M ($32.6M current, $531.7M long-term as booked net of issuance costs); 2029 Convertible Notes $241.5M principal (booked at $238.5M net of issuance costs, but face-value liability is $241.5M); operating lease obligations $5.2M; contingent consideration current $17.6M (Jornay PM milestone); accrued liabilities $58.1M; accounts payable $6.8M; plus other current liabilities. Total face-value liabilities approximate $1.14B+. Net recovery to equity is substantially negative, consistent with MFFAIS CLV of -$170M. The LLV of +$59M and OLV of +$101M reflect the liquid-asset-heavy balance sheet but ignore the subordinated nature of equity below $814M of funded debt principal at face. A critical forward event: the pending Azstarys acquisition ($650M cash upfront, funded by existing cash plus drawing $300M delayed draw term loan) will, upon close in Q2 2026, materially increase debt and reduce cash, deepening the negative liquidation recovery. The deferred royalty obligation on Jornay PM and minimum purchase commitments with contract manufacturers are disclosed in MD&A but are not separately XBRL-tagged in this filing, making their exact quantum unquantifiable from the tag set alone. Intangible asset amortization of $55.5M/quarter is expected to decline materially during 2026 as Belbuca and Nucynta Products intangibles reach full amortization, which will shift asset composition toward cash over time if debt is repaid concurrently.
▼ Community Notes